COMMUNIQUÉS West-GlobeNewswire

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
14/05/2024
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2024
14/05/2024
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial [...]
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
14/05/2024
Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host [...]
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected [...]
Iridex Reports First Quarter 2024 Financial Results
14/05/2024
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14/05/2024
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today reported [...]
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
14/05/2024
Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC) Could Represent an Important New Innovation for Optimizing Immunosuppressive Therapy in Lung Transplant [...]
NeuroPace to Participate in Two Healthcare Conferences in May
14/05/2024
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in [...]
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD [...]
AEON Biopharma Reports First Quarter 2024 Financial Results
14/05/2024
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company’s late-stage clinical [...]
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing [...]
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
14/05/2024
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2 Bolt to cease further development of [...]
Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
Successfully ramped up limited U.S. commercial launch of the Pure-Vu ® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded [...]
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
14/05/2024
- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib - - First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of Concept Study - - [...]
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
14/05/2024
Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024; 12-month non-human [...]
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
14/05/2024
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- MEACOR Inc. is pleased to announce the successful closing of its $15 million Series A funding round. This substantial investment supports MEACOR’s mission to offer a novel [...]
L’Arche Greater Vancouver Receives Million Dollar Donation from a B.C. Family Foundation
14/05/2024
BURNABY, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- L’Arche Greater Vancouver gratefully announces that its We All Belong campaign has received a second major donation from the same family Foundation . In 2019, [...]
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
14/05/2024
- Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024 COPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) [...]

Pages